FilingReader Intelligence
Alembic Pharmaceuticals gets US approval for $1.18bn drug
August 19, 2025 at 06:09 AM UTC•By FilingReader AI
Alembic Pharmaceuticals received US FDA approval for Macitentan Tablets, used to treat pulmonary arterial hypertension.
The drug has an estimated market size of $1.18 billion for the twelve months ending June 2025. This brings Alembic's total FDA approvals to 224.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:APLLTD•Bombay Stock Exchange
News Alerts
Get instant email alerts when ALEMBIC PHARMACEUTICALS publishes news
Free account required • Unsubscribe anytime